BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25680240)

  • 1. The Era of Prostate-specific Antigen-based Personalized Prostate Cancer Screening Has Only Just Begun.
    Schlomm T
    Eur Urol; 2015 Aug; 68(2):214-5. PubMed ID: 25680240
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-Specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.
    Taneja SS
    J Urol; 2015 Aug; 194(2):393-4. PubMed ID: 26195364
    [No Abstract]   [Full Text] [Related]  

  • 3. The dilemmas of prostate cancer screening.
    Hugosson J; Carlsson SV
    Med J Aust; 2013 Jun; 198(10):528-9. PubMed ID: 23725256
    [No Abstract]   [Full Text] [Related]  

  • 4. Toward a smarter prostate cancer screening program.
    Sjoberg DD
    Eur Urol; 2015 Oct; 68(4):598-9. PubMed ID: 24836056
    [No Abstract]   [Full Text] [Related]  

  • 5. Managing localized prostate cancer in the era of prostate-specific antigen screening.
    Brooks JD
    Cancer; 2013 Nov; 119(22):3906-9. PubMed ID: 24006273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer screening can save lives but it is too early for a national programme, study finds.
    Sayburn A
    BMJ; 2014 Aug; 349():g5055. PubMed ID: 25102993
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of Prostate-Specific Antigen Screening: Use of Regression Discontinuity in the PLCO Cancer Screening Trial.
    Shoag J; Halpern J; Eisner B; Lee R; Mittal S; Barbieri CE; Shoag D
    JAMA Oncol; 2015 Oct; 1(7):984-6. PubMed ID: 26291583
    [No Abstract]   [Full Text] [Related]  

  • 8. Should we screen for prostate cancer? A re-examination of the evidence.
    Del Mar CB; Glasziou PP; Hirst GH; Wright RG; Hoffmann TC
    Med J Aust; 2013 Jun; 198(10):525-7. PubMed ID: 23725255
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate cancer: Rescreening policies and risk calculators.
    Roobol MJ
    Nat Rev Urol; 2014 Aug; 11(8):429-30. PubMed ID: 24980199
    [No Abstract]   [Full Text] [Related]  

  • 10. First, do no harm.
    Pimlott N
    Can Fam Physician; 2012 Sep; 58(9):915. PubMed ID: 22972717
    [No Abstract]   [Full Text] [Related]  

  • 11. Doing it right: how, not whether, to perform prostate-specific antigen screening.
    Martin NE
    Eur Urol; 2015 Sep; 68(3):361-2. PubMed ID: 25794459
    [No Abstract]   [Full Text] [Related]  

  • 12. Future of screening for prostate cancer.
    Dahm P
    BMJ; 2017 Sep; 358():j4200. PubMed ID: 28928226
    [No Abstract]   [Full Text] [Related]  

  • 13. Prostate-specific antigen screening for prostate cancer in males older than 75 years.
    Luján M; Páez Á
    Med Clin (Barc); 2019 Mar; 152(6):237-240. PubMed ID: 30220470
    [No Abstract]   [Full Text] [Related]  

  • 14. Next-generation prostate-specific antigen test: ready to use?
    Bjartell AS
    Eur Urol; 2013 Nov; 64(5):700-2. PubMed ID: 23850253
    [No Abstract]   [Full Text] [Related]  

  • 15. Unorganized prostate-specific antigen-based screening for prostate cancer: more harm than benefit. When will we finally start to implement guidelines and risk assessment tools in clinical practice?
    Roobol MJ
    Eur Urol; 2015 Sep; 68(3):363-4. PubMed ID: 25769985
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to the letter to the editor 'Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis' by Louie et al.
    Louie KS; Seigneurin A; Cathcart P; Sasieni P
    Ann Oncol; 2015 May; 26(5):1031-1032. PubMed ID: 25672895
    [No Abstract]   [Full Text] [Related]  

  • 17. Letter to the editor concerning 'Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis'.
    Carlsson S; Assel M; Vickers A
    Ann Oncol; 2015 May; 26(5):1031. PubMed ID: 25646367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer: treatment-specific nomograms, biochemical recurrence, and prostate cancer-specific mortality.
    Phillips R
    Nat Rev Urol; 2014 Dec; 11(12):657. PubMed ID: 25330792
    [No Abstract]   [Full Text] [Related]  

  • 19. Baseline PSA testing for men in their 40s: currently available evidence strongly supports baseline PSA measurements in this age group.
    Catalona WJ
    Oncology (Williston Park); 2014 Feb; 28(2):154, 156. PubMed ID: 24701705
    [No Abstract]   [Full Text] [Related]  

  • 20. Can the results of the European Randomized Study of Screening for Prostate Cancer be decontaminated?
    Metcalfe C
    Eur Urol; 2014 Feb; 65(2):337-8; discussion 338-9. PubMed ID: 24050792
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.